Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Alnylam Pharmaceuticals Inc shares valued at $9,630,902 were sold by Greenstreet Yvonne on May 30 ’25. At $304.39 per share, Greenstreet Yvonne sold 31,640 shares. The insider’s holdings dropped to 48,948 shares worth approximately $19.2 million following the completion of this transaction.
Also, Greenstreet Yvonne sold 19,297 shares, netting a total of over 5,904,882 in proceeds. Following the sale of shares at $306.00 each, the insider now holds 48,948 shares.
Before that, Greenstreet Yvonne had added 19,297 shares to its account. In a trade valued at $5,848,824, the Officer bought Alnylam Pharmaceuticals Inc shares for $303.10 each.
Analysts at Truist started covering the stock with ‘”a Buy”‘ outlook in a report released in late July. As of March 31, 2025, Redburn Atlantic has initiated its “Buy” rating for ALNY. Earlier on March 24, 2025, JP Morgan upgraded its rating. Their new recommendation was “an Overweight” for ALNY stock which previously was a “a Neutral”.
Analyzing ALNY Stock Performance
On last trading session, Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] rose 15.43% to $392.24. The stock’s lowest price that day was $350.0, but it reached a high of $402.4313 in the same session. During the last five days, there has been a surge of approximately 19.59%. Over the course of the year, Alnylam Pharmaceuticals Inc shares have jumped approximately 66.01%. Shares of the company reached a 52-week high of $402.43 on 07/31/25 and a 52-week low of $205.87 on 04/09/25.
Support And Resistance Levels for Alnylam Pharmaceuticals Inc (ALNY)
According to the 24-hour chart, there is a support level at 360.68, which, if violated, would cause prices to drop to 329.13. In the upper region, resistance lies at 413.11. The next price resistance is at 433.99. RSI (Relative Strength Index) is 82.96 on the 14-day chart, showing overbought technical sentiment.
Is Alnylam Pharmaceuticals Inc subject to short interest?
Stocks of Alnylam Pharmaceuticals Inc saw a sharp rise in short interest on 2025-07-15 jumping by 3658.0 shares to 3.38 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 3.38 million shares. A jump of 0.11% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.7 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.7.
Which companies own the most shares of Alnylam Pharmaceuticals Inc (ALNY)?
In terms of Alnylam Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 365 in the next 12 months, up nearly 7.42% from the previous closing price of $339.8. Analysts anticipate Alnylam Pharmaceuticals Inc stock to reach 385 by 2025, with the lowest price target being 338. In spite of this, 20 analysts ranked Alnylam Pharmaceuticals Inc stock as Buy at the end of 2025.
